Targeted Therapies for Relapsed or Refractory Classical Hodgkin Lymphoma

This information was originally presented at the NCCN 10th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Review the clinical evidence from ongoing trials evaluating novel treatment options and the potential role of new agents in the treatment algorithm for patients with relapsed or refractory CHL
Additional information
Supporters: 

This activity is supported by educational funding provided by Amgen.

This activity is supported by an independent educational grant from Incyte Corporation.

This activity is supported by educational grants from:

  • AbbVie Inc.
  • Actelion Pharmaceuticals US, Inc.
  • Astellas Scientific and Medical Affairs, Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genentech
  • Gilead Sciences, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seattle Genetics
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Oncology
Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.44 ANCC contact hours
  • 0.50 Participation
Course opens: 
12/01/2015
Course expires: 
12/01/2016
Cost:
$0.00

Weiyun Z. Ai, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below has no relevant financial relationships to disclose:

Weiyun Z. Ai, MD, PhD

NCCN Staff Disclosures

The activity planning staff listed below has no relevant financial relationships to disclose:
Robert W. Carlson, MD; Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Lisa G. Kimbro, CPA, MBA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:

Jennifer Burns; Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: December 1, 2015
Expiration date: December 1, 2016

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.44 contact hour. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Release date: December 1, 2015
Expiration date: December 1, 2016

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge 

National Comprehensive Cancer Network designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-109-H01-P

Release date: December 1, 2015
Expiration date: December 1, 2016

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.44 ANCC contact hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing